Colistimethate Sodium
An inactive prodrug that is hydrolyzed to the active antibiotic colistin in body fluids, used intravenously or by inhalation to treat serious infections caused by multidrug-resistant Gram-negative bacteria. It is considered a last-resort antibiotic due to its kidney toxicity.
Masse moléculaire
968,2000 g/mol
LogP
-0,70
TPSA
386,00 Ų
Règle des 5 de Lipinski
Non conforme
Aires thérapeutiques
Mécanisme d'action
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Structure 2D
Cite this structure
Embed this structure
SMILES
CCC(C)CCCCC(=O)NCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(C)C)CCN)CC(C)C)CCN)CCN)CCN)[C@@H](C)O
InChI
InChI=1S/C45H85N13O10/c1-8-27(6)11-9-10-12-36(60)50-22-17-33-42(65)58-37(28(7)59)45(68)55-32(16-21-49)39(62)51-29(13-18-46)38(61)52-30(14-19-47)40(63)56-34(23-25(2)3)43(66)53-31(15-20-48)41(64)57-35(24-26(4)5)44(67)54-33/h25-35,37,59H,8-24,46-49H2,1-7H3,(H,50,60)(H,51,62)(H,52,61)(H,53,66)(H,54,67)(H,55,68)(H,56,63)(H,57,64)(H,58,65)/t27?,28-,29+,30+,31+,32+,33+,34+,35+,37+/m1/s1
Molecular Formula
C45H85N13O10
HBD / HBA
14 / 14
Liaisons Rotatives
22
Atomes Lourds
68
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
An inactive prodrug that is hydrolyzed to the active antibiotic colistin in body fluids, used intravenously or by inhalation to treat serious infections caused by multidrug-resistant Gram-negative bacteria. It is considered a last-resort antibiotic due to its kidney toxicity.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Colistimethate Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201441. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 44585614. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="colistimethate-sodium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/colistimethate-sodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/colistimethate-sodium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/colistimethate-sodium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="colistimethate-sodium"></drugfyi-drug>